Transparency In Alzheimer’s: AdComm Expected On Regular Approval For Eisai/Biogen’s Leqembi

 
• By Sue Sutter
Squeegee on window
An adcomm would provide a clearer picture of the FDA's review of the lecanemab sBLA. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers